AI Article Synopsis
- The study aimed to explore how variations in the LRP5 gene affect the effectiveness of alendronate treatment in women with osteoporosis in China.
- The research involved 639 postmenopausal women who were treated with alendronate, and the A1330V polymorphism in LRP5 was examined alongside changes in bone mineral density and bone turnover markers before and after treatment.
- Results showed that women with CC and CT genotypes experienced more significant improvements in lumbar spine bone density and decreases in specific bone turnover markers than those with the TT genotype, indicating that the TT genotype may signal a weaker response to the medication.
Article Abstract
Aim: To investigate the association between LRP5 gene polymorphisms and response to alendronate in Chinese osteoporotic women.
Materials & Methods: Six hundred and thirty nine Chinese postmenopausal women with osteopenia or osteoporosis were included and received alendronate treatment. The A1330V polymorphism of LRP5 was investigated. Bone mineral density (BMD) and bone turnover markers (ALP and β-isomerized carboxy-telopeptide of type I collagen [β-CTX]) were measured before and after treatment. The correlation of LRP5 polymorphisms with changes in BMD and bone turnover biomarkers were analyzed after treatment.
Results: After 12 months of treatment, participants with CC and CT genotypes had a larger increase in lumbar spine BMD and a larger decrease in serum β-CTX and ALP levels than those with TT genotype (all p < 0.001). No significant genotype-treatment interaction was found in hip BMD.
Conclusion: The A1330V polymorphism of LRP5 is possibly correlated with response to alendronate treatment in Chinese women with osteoporosis, and the TT genotype could possibly predict a weak response to alendronate.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pgs.14.12 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Design and evaluation of a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma.
Int J Pharm
January 2025
Key Laboratory of Modern Preparation of TCM, Ministry of Education, Jiangxi University of Chinese Medicine, Nanchang 330004 China; School of Pharmaceutics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211198 China. Electronic address:
The combination of chemotherapy and photothermal therapy not only improves the therapeutic effect but also limits the side effects of drugs. Herein, a multi-responsive dual-modality bone-targeted drug delivery vehicle for the treatment of osteosarcoma was designed by utilizing alendronate sodium as a bone-targeting ligand for the targeted delivery of doxorubicin (DOX) loaded polydopamine nanoparticles (PDA NPs) coated with γ-polyglutamic acid (APC@PDA/DOX NPs). The average size of spherical NPs was 140.
View Article and Find Full Text PDFMultifaceted Catalytic Glucose Depletion and Reactive Oxygen Species-Scavenging Nanoenzyme Composite Hydrogel for Facilitating Diabetic Bone Regeneration.
ACS Nano
January 2025
National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, P. R. China.
Regeneration of diabetic bone defects remains a formidable challenge due to the chronic hyperglycemic state, which triggers the accumulation of advanced glycation end products (AGEs) and reactive oxygen species (ROS). To address this issue, we have engineered a bimetallic metal-organic framework-derived Mn@CoO@Pt nanoenzyme loaded with alendronate and Mg ions (termed MCPtA) to regulate the hyperglycemic microenvironment and recover the osteogenesis/osteoclast homeostasis. Notably, the Mn atom substitution in the CoO nanocrystalline structure could modulate the electronic structure and significantly improve the SOD/CAT catalytic activity for ROS scavenging.
View Article and Find Full Text PDFOsteosarcoma-targeting Pt prodrug amphiphile for enhanced chemo-immunotherapy via Ca trapping.
Acta Biomater
December 2024
Department of Pharmaceutics, School of Pharmacy, Qingdao University, Qingdao 266021, China. Electronic address:
Platinum (Pt)-based anticancer agents exhibit a lack of selectivity in the treatment of osteosarcoma, resulting in significant toxicity. Furthermore, immune surveillance withinthe tumor microenvironment impedes the uptake of platinum drugs by osteosarcoma cells. To overcome these challenges, an oxaliplatin-based Pt prodrug amphiphile (Lipo-OXA-ALN) was designed and synthesized by incorporatingan osteosarcoma-targeting alendronate (ALN) alongside a lipid tail.
View Article and Find Full Text PDFCombining systemic and local osteoporosis treatments: A longitudinal in vivo microCT study in ovariectomized rats.
Bone
December 2024
Laboratory of Biomechanical Orthopedics, Institute of Bioengineering, EPFL, Lausanne, Switzerland.
Introduction: Managing osteoporotic patients at immediate fracture risk is challenging, in part due to the slow and localized effects of anti-osteoporotic drugs. Combining systemic anti-osteoporotic therapies with local bone augmentation techniques offers a promising strategy, but little is known about potential interactions. We hypothesized that integrating systemic treatments with local bone-strengthening biomaterials would have an additive effect on bone density and structure.
View Article and Find Full Text PDFDynamic Covalent Prodrug Nanonetworks via Reaction-Induced Self-Assembly for Periodontitis Treatment.
ACS Nano
December 2024
Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, Translational Medicine Laboratory, The First Affiliated Hospital of Wenzhou Medical University institution, Wenzhou, Zhejiang 325035, China.
Periodontitis is characterized by dysbiotic biofilms, gingival inflammation, and bone resorption, highlighting the urgent need for a comprehensive approach to drug combination therapy. In this study, we introduce dynamic covalent nanonetworks (dcNNWs) synthesized through a one-pot, four-component reaction-induced self-assembly method using polyamines, 2-formylphenylboronic acid, epigallocatechin gallate, and alendronate. The formation of iminoboronate bonds drives the creation of dcNNWs, allowing controlled release in the periodontitis microenvironment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!